# Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/par-22-111-early-stage-preclinical-validation-of-therapeutic-leads-for/  
Official notice: https://www.grants.gov/search-results-detail/337854

> National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 7, 2025.

| Field | Value |
|---|---|
| Opportunity number | PAR-22-111 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | January 7, 2025 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.847 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available a www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx and applicants are strongly encouraged to discuss research priorities with the Scientific Contact.

## Questions people ask

### Is PAR-22-111 still open?

No. It closed on January 7, 2025.

### Who can apply for Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)?

Closed January 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under PAR-22-111?

NIH RePORTER lists 3 projects funded under PAR-22-111 in fiscal 2023 to 2026, at 3 institutions. The most were at Vanderbilt University Medical Center, Sanford Burnham Prebys Medical Discovery Institute, Brigham and Women's Hospital.

### Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.